As many as 16,946 new COVID-19 cases were recorded in the last 24 hours, taking the total number of confirmed coronavirus cases to 1,05,12,093, as per Union Health Ministry's latest bulletin released on Thursday.
The vaccination drive against coronavirus will kick off on January 16, 2021. The priority will be given to the healthcare workers and the frontline workers, estimated to be around 3 crore.
In a significant development, Drugs Controller General of India (DGCI) on Sunday (January 3) formally approved Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin for use in India.
Taking to Twitter, Congress MP Shashi Tharoor said, "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous."
Senior Congress leader Anand Sharma on Sunday raised concerns over India's drugs regulator granting permission for the restricted use of Bharat Biotech's COVID-19 vaccine and asked the government to explain why mandatory protocols and verification of
In a significant development, Drugs Controller General of India (DGCI) on Sunday (January 3) formally approved Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin for use in India.
The panel has recommended to the government that any vaccine against COVID-19 should be granted emergency use authorisation only after proper consideration and conducting its trials on a sufficient sample size.
The expert panel has recommended granting permission for restricted emergency use of 'Covaxin' in "public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains.
A total of 1,47,901 deaths have been reported so far in the country including 49,255 from Maharashtra followed by 12,062 from Karnataka, 12,069 from Tamil Nadu, 10,453 from Delhi, 9,598 from West Bengal, 8,306 from Uttar Pradesh, 7,094 from Andhra Pradesh and 5,299 from Punjab.
The coronavirus crisis is now 'on its way out' and 'soon' vaccines would be available in India too, Union Information and Broadcasting Minister Prakash Javadekar said on Monday. He was speaking at the International Coronavirus Short Film Festival.
India's coronavirus active caseload has dipped to 4.03 lakh, the lowest after 138 days, comprising 4.18 per cent of the total COVID-19 infections reported so far in the country, Union Health Ministry said on Sunday.
India's coronavirus active cases have remained below the 5-lakh mark, with its share further shrinking to 4.60 per cent of the total COVID-19 infections reported so far, Union Health Ministry on Tuesday informed.
According to the ICMR, over 13.17 crore samples have been tested up to November 22 with 10,75,326 samples being tested on Saturday.
From the development of indigenous vaccines to novel point-of-care diagnostics, India has initiated an integrated response to overcome the unprecedented COVID-19 pandemic, Union minister Harsh Vardhan said on Saturday.
India has conducted the second-highest number of tests for detection of COVID-19 in the world at 11.96 crore with rapid antigen tests comprising 49 per cent and RT-PCR 46 per cent of the total tests done till Tuesday morning, the Union Health Ministry said.
India's COVID-19 case fatality rate (CFR) fell below 1.5 per cent on Saturday, the Union health ministry said, crediting the Centre-led strategy of 'test, trace, track and treat' for keeping coronavirus-related deaths low and within manageable numbers.
Drug firm Cipla on Wednesday announced the launch of antibody detection kits for COVID-19 in India under the brand name 'ELIFast' in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).
This achievement is matched by the downward spiral fall in the number of active COVID-19 cases, which was maintained below the seven-lakh mark for the third successive day.
Scientists from around the world, including India are developing several vaccines that are at different stages of clinical trials. The central government maintains it has started to gear up to take these vaccines to every citizen.
Variation in a genetic mutation among Indians may be the main reason behind the difference in the death rates due to COVID-19 across various states of the country, says a study that could inform new policies for controlling the novel coronavirus pandemic.
Top News
Latest News
